Rosmarinic acid inhibits the proliferation of ovarian carcinoma cells by activating the p53/BAX signaling pathway

Basit Öğe Kaydı
dc.contributor.authorOzdemir, Ilhan
dc.contributor.authorBas, Dilek Dogan
dc.contributor.authorOzturk, Samil
dc.contributor.authorKaraosmanoglu, Ozge
dc.contributor.authorTuncer, Mehmet Cudi
dc.date.accessioned2026-02-03T12:00:24Z
dc.date.available2026-02-03T12:00:24Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective. While chemotherapeutic agents stop the development of cancer cells, they also kill healthy cells. This study aimed to increase anticancer effects and reduce side effects by combining a phytotherapeutic compound with a chemotherapeutic drug. Methods. This study examined the effects of nine concentrations of rosmarinic acid (RA) and doxorubicin (DOX) on human ovarian adenocarcinoma (OVCAR3) and skin keratinocyte (HaCaT) cell lines. Their cytotoxic effects were assessed based on cell viability, evaluated using the MTT assay, and apoptotic activity, evaluated using NucBlue staining and the gene and protein expression of tumor protein p53 (TP53) and BCL2 associated X, apoptosis regulator (BAX) quantified by qRT-PCR and western blots, respectively. Results. The half-maximal inhibitory concentration after 48 hours was 880.4 mu M for RA and 2.26 mu M for DOX. The cytotoxicity analysis revealed that cell viability decreased with the RA concentration. RA increased apoptosis in OVCAR3 cells by activating the p53/BAX pathway. Western blots showed that RA and DOX upregulated p53 and BAX protein levels in OVCAR3 cells. Conclusions. The RA and DOX combination inhibited cell proliferation by inducing apoptosis in OVCAR3 cells. These results suggest that RA may reduce the side effects of DOX toxicity.
dc.identifier.doi10.14670/HH-18-883
dc.identifier.endpage1423
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.issue9
dc.identifier.pmid39945236
dc.identifier.scopus2-s2.0-105013122216
dc.identifier.scopusqualityQ2
dc.identifier.startpage1415
dc.identifier.urihttps://doi.org/10.14670/HH-18-883
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34601
dc.identifier.volume40
dc.identifier.wosWOS:001572017000009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherF Hernandez
dc.relation.ispartofHistology and Histopathology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectRosmarinic acid
dc.subjectOvarian cancer
dc.subjectOVCAR3
dc.subjectApoptosis
dc.subjectqRT-PCR
dc.subjectCell death
dc.titleRosmarinic acid inhibits the proliferation of ovarian carcinoma cells by activating the p53/BAX signaling pathway
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu